Literature DB >> 9479681

Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).

J D Bremner1, J H Krystal, F W Putnam, S M Southwick, C Marmar, D S Charney, C M Mazure.   

Abstract

The purpose of this study was to develop an instrument for the measurement of present-state dissociative symptoms, the Clinician Administered Dissociative States Scale (CADSS). Reported here are interrater reliability and internal consistency of the CADSS, validity as assessed by comparisons with other instruments for the assessment of dissociation, and sensitivity of the CADSS to discriminate patients with dissociative disorders from patients with other psychiatric disorders and healthy subjects. Initial analyses indicated good interrater reliability and construct validity for the CADSS. Scores on the CADSS discriminated patients with dissociative disorders from the other groups.

Entities:  

Mesh：

Year:  1998        PMID： 9479681     DOI： 10.1023/A:1024465317902

Source DB:  PubMed          Journal:  J Trauma Stress        ISSN： 0894-9867


  191 in total

1.  A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.

Authors:  Lobna Ibrahim; Nancy Diaz Granados; Libby Jolkovsky; Nancy Brutsche; David A Luckenbaugh; W Joseph Herring; William Z Potter; Carlos A Zarate
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

2.  Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.

Authors:  T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta
Journal:  Psychopharmacology (Berl)       Date:  2015-10-05       Impact factor: 4.530

3.  In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.

Authors:  Christine DeLorenzo; Nicole DellaGioia; Michael Bloch; Gerard Sanacora; Nabeel Nabulsi; Chadi Abdallah; Jie Yang; Ruofeng Wen; J John Mann; John H Krystal; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  Biol Psychiatry       Date:  2014-07-10       Impact factor: 13.382

4.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

5.  Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Authors:  Marlene P Freeman; George I Papakostas; Bettina Hoeppner; Erica Mazzone; Heidi Judge; Cristina Cusin; Sanjay Mathew; Gerard Sanacora; Dan Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Psychiatr Res       Date:  2019-01-08       Impact factor: 4.791

6.  Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism.

Authors:  James Edward Bryant; Michael Frölich; Steve Tran; Meredith Amanda Reid; Adrienne Carol Lahti; Nina Vanessa Kraguljac
Journal:  J Psychiatr Res       Date:  2019-07-27       Impact factor: 4.791

7.  Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.

Authors:  Elia E Acevedo-Diaz; Grace W Cavanaugh; Dede Greenstein; Christoph Kraus; Bashkim Kadriu; Lawrence Park; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2020-07-30       Impact factor: 4.791

8.  Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence.

Authors:  Agnes Norbury; Sarah B Rutter; Abigail B Collins; Sara Costi; Manish K Jha; Sarah R Horn; Marin Kautz; Morgan Corniquel; Katherine A Collins; Andrew M Glasgow; Jess Brallier; Lisa M Shin; Dennis S Charney; James W Murrough; Adriana Feder
Journal:  Neuropsychopharmacology       Date:  2021-07-31       Impact factor: 7.853

9.  Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo.

Authors:  Garry D Honey; Philip R Corlett; Anthony R Absalom; Michael Lee; Edith Pomarol-Clotet; Graham K Murray; Peter J McKenna; Edward T Bullmore; David K Menon; Paul C Fletcher
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

10.  Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Authors:  Laura E Phelps; Nancy Brutsche; Jazmin R Moral; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2008-11-08       Impact factor: 13.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.